Report Overview

Germanys Breast Cancer Therapeutics market size stood at around USD XX.X billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 8.9% during the forecast period.

Increased Incidence coupled with growing awareness contributes to the growth of this market. The growing cases of breast cancer in the country further propel the demand for diagnostics and further treatment facilities for breast cancer thus contributing to the market growth. According to the quality assured Mammography Screening Program in Germany, women between 50 and 69 years of age are invited to an X-ray examination of the breasts every two years.



Market Driving and Restraining Factors

Market Drivers

The driving factors for the growth of the Breast Cancer Therapeutics market in Germany include:

• 
  
  
  
  • Rising prevalence of Breast cancer
  
  
  • Growing healthcare spending for cancer
  
  
  • Launch of technologically advanced therapeutics
  
  
  
  

One of the foremost drivers influencing the growth of the German market is the increased prevalence of breast cancer across the world, which is expected to result in a large patient population demanding accurate and efficient treatment options. Furthermore, the increasing demand for preventive care and early treatment has led many individuals to undergo cancer screening tests, which would also strongly drive the number of patients demanding treatment in the forecast period. As the number of patients suffering from breast cancer continues to increase, the importance and the critical need for the development of advanced therapeutics for better outcomes remains unparalleled.

Restraining Factors

• 
  
  
  
  • Adverse effects of therapeutics
  
  
  
  

Adverse reactions arising from breast cancer therapeutics, such as targeted therapies, may limit the market growth soon. In cases of severe adverse reactions, the patient may not be able to use that drug and may have to move toward other types of therapeutics.

Breast Cancer Stages

The stages of breast cancer are determined by cancers characteristics, such as how large it is and whether it has hormone receptors. These stages are classified as:

• 
  
  
  
  • Stage 0
  
  
  • Stage I
  
  
  • Stage 2
  
  
  • Stage 3
  
  
  • Stage 4
  
  
  
  

Incidence rates in the observation period increased, as they were affected by the increasing number of cases with early-stage cancers being diagnosed in the screening age group. The total incidence of early-stage cancer, which included the incidence of non-invasive breast cancers, increased by 14.5% between 2005 and 2016.

Advanced stage breast cancer rates (UICC II+) started to decline during fully implemented screening program. Advanced stage breast cancer declines were not observed in women newly eligible for screening

Early-stage cancers (UICC stages 0 and I) increased by 48.1% while late-stage diagnoses (UICC stages III and IV) decreased by 31.6%.

These changes can be attributed to developing infrastructure and expertise in the breast cancer market.